Sandoz announced today that it has enrolled its first patient in a combined phase 1 and phase 3 study of its proposed denosumab biosimilar versus EU-authorized Prolia.
Sandoz announced today that it has enrolled its first patient in a combined phase 1 and phase 3 study of its proposed denosumab biosimilar versus EU-authorized Prolia.
Denosumab, a monoclonal antibody that inhibits the RANKL protein and thereby decreases the production of osteoclasts, is indicated for a number of conditions, including osteoporosis in postmenopausal women, increased fracture risk in men, a treatment-induced bone loss, among others.
“People with the bone disease osteoporosis are more likely to fracture or break a bone, causing pain and restriction of mobility, which can be extremely debilitating,” said Florian Bieber, global head of development at Sandoz, in a statement announcing the trial. “As we progress our development program for proposed biosimilar denosumab, we believe it gives patients hope for early and expanded access to advanced biologic medicines, which may change the course of their disease.”
The study, ROSALIA, is a multicenter, randomized, parallel-arm, double-blind study with a total duration of up to 82 weeks. The drug maker plans to enroll approximately 522 postmenopausal patients with osteoporosis for 2 treatment periods.
In the first period of 52 weeks, patients will be randomized to receive 2 doses of either GP2411 or the EU-authorized reference product.
In the second treatment period, from week 52 to week 78, patients who received the reference denosumab in the first period will be rerandomized either to continue to receive the reference or to switch to GP2411. All patients in the biosimilar group will continue with a third dose of GP2411.
The study’s primary end points include percentage change in lumbar spine bone mineral density, and the drug maker expects to complete the study by June 2022.
The reference drug, Prolia, has been a strong seller for Amgen, the innovator behind denosumab. In first quarter 2019 financial results, Amgen said that the drug had brought in $390 million in the United States and $202 million in the rest of the world. Those sales were up 20% year over year, said the company, driven by higher unit demand.
Other biosimilar developers targeting denosumab include Australian drug maker NeuClone; the company announced in early 2018 that it had entered early-stage development of a proposed biosimilar.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim
November 25th 2023A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).